Smith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., Boegemann, M., Matveev, V., Piulats, J. M., Zucca, L. E., Karyakin, O., Kimura, G., Matsubara, N., Nahas, W. C., Nolè, F., Rosenbaum, E., Heidenreich, A., Kakehi, Y., Zhang, A., Krissel, H., Teufel, M., Shen, J., Wagner, V., & Higano, C. (2019). addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, 20(3), 408–419. http://access.bl.uk/ark:/81055/vdc_100077974659.0x000013